Tumor DNA Methylation Profiles Enable Diagnosis, Prognosis Prediction, and Screening for Cervical Cancer

Jiannan Tu,Shengchi Chen,Shizhen Wu,Ting Wu,Renliang Fan,Zhixing Kuang

DOI: https://doi.org/10.2147/IJGM.S352373

IF: 2.145

2022-06-28

International Journal of General Medicine

Abstract:Jiannan Tu, 1, &ast Shengchi Chen, 1, &ast Shizhen Wu, 1, &ast Ting Wu, 1, &ast Renliang Fan, 1 Zhixing Kuang 2 1 Department of Oncology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, 353000, People's Republic of China; 2 Department of Radiation Oncology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, 353000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhixing Kuang, Department of Radiation Oncology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, 353000, People's Republic of China, Email Background: DNA-methylation-based machine learning algorithms have demonstrated powerful diagnostic capabilities, and these tools are currently emerging in many fields of tumor diagnosis and patient prognosis prediction. This work aimed to identify novel DNA methylation diagnostic biomarkers for differentiating cervical cancer (CC) from normal tissues, as well as a prognostic prediction model to predict survival of CC patients. Methods: The methylation profiles with the available clinical characteristics were downloaded from the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) program. We first screened out the differential methylation sites in CC and normal tissues and performed multiple statistical analyses to discover DNA methylation diagnostic markers that are used to distinguish CC and normal control. Then, we developed a methylation-based survival model to improve risk stratification. Results: A diagnostic prediction panel consists of five CpG markers that could predict cervical cancer versus normal tissue with highly correct rate of 100%, and cg16428251, cg22341310, and cg23316360 which in diagnostic prediction panel all could yield high sensitivity and specificity for detection of CC and normal in six cohorts (area under curve [AUC] > 0.8), in addition to excellent performance in discriminating between CC and normal sample. The diagnostic marker panel also effectively predicted the CIN3 versus normal tissue with high accuracy in two datasets (AUC = 0.80, 0.789, respectively). Furthermore, a prognostic prediction model aggregated two CpG markers that effectively stratified the prognosis of high-risk and low-risk groups (training cohort: hazard ratio [HR] 4, 95% CI: 1.7– 9.6, P = 0.0021; testing cohort: hazard ratio [HR] 1.9, 95% CI: 1.2– 3.1, P = 0.0072). Conclusion: The findings of our study showed that DNA methylation markers are of great value in the diagnosis and prognosis of CC. Keywords: cervical cancer, DNA methylation, markers, diagnosis, prognosis Cervical cancer (CC) is a kind of gynecological malignant disease that accounts for 570,000 new cases and 311,000 deaths worldwide each year and continues to be listed among the top gynecological cancers worldwide, only behind breast cancer worldwide. 1,2 Despite the efforts in vaccination that have been made to reduce the incidence of CC, it is estimated that approximately 13,800 new cases of CC will be diagnosed among the most developed countries like the United States in 2020, and nearly 4290 women will die of this disease. 3 The situation in low-income areas still needs improvement, and CC is far from being eradicated. The overall 5-year survival rate of all CC patients is 68% and in patients with recurrent or metastatic CC survival remains poor, with a 5-year survival rate of 17%. 4,5 CC can be easily treated if detected at early stages, 6 thus there is a need for reliable approaches that will allow early diagnosis for this type of cancer to improve prognosis. Testing for human papillomavirus (HPV) DNA is most widely utilized for detection and surveillance of CC due to persistent infections of high-risk human papillomavirus (hrHPV). It is a causative agent that leads to high-grade precancerous cervical lesions and can progress to CC, 7 but not all patients infected with HPV will progress to invasive CC. Thus, there is an urgent need to look for novel biomarkers beyond HPV detection which relate to the stepwise progression from cervical intraepithelial neoplasia (CIN2/CIN3) to invasive CC. The influence of epigenetic changes which encompass DNA methylation, histone modifications, and non-coding RNAs on tumor progression and clinical outcomes has been widely described for different cancers. 8 Epigenetic alterations occur in the early or precancerous process of carcinogenesis and are considered as the precursor of malignant CC. 9,10 Therefore, the discovery of new epigenetic biomarkers can -Abstract Truncated-

medicine, general & internal